A New Standard for Disease Analysis

Revolutionary immunotherapies for complex, heterogeneous diseases

Contact Us

About Remedy Biologics

Based in Dublin, RemedyBio is a nano scale biotechnology company pioneering ultra high throughput therapeutic and diagnostic discovery. The company’s discovery technology massively improves the speed and scale of single cell analysis, with next-generation applications in immunoncology, autoimmune disease, and infectious disease.

Deep analysis of individual cell function of 10M-1Bn individual living cells

Very large scale, cell by cell combinational biology studying healthy tissue, disease biology, and immune function simultaneously

Disease characterisation based on statistical and machine analysis across millions or billions of cell results – for example from patient tumour biopsies

Sequencing, replication or banking of post-assay biology for therapeutic design or long term asset building

Leadership Team

Dan Crowley

CEO & Co-Founder

Dan Crowley is co-founder and CEO of RemedyBio, and is focused on strategic leadership of the company, supporting our great team, and building transformational partnerships with industry leaders. Prior to RemedyBio, Dan co-founded and led Genomics Medicine Ireland (acquired in 2018) and was a Venture Partner with ARCH Venture Partners.

He serves on the board of the AMBER Centre for Advanced Materials and Bioengineering Research headquartered at Trinity College Dublin. Dan holds a BA and MSc from Trinity College Dublin, a PDip from Oxford University, received his MBA from Cornell where he was an Angear Merit Scholar, and is a Kauffman Fellow.

Paul Leonard

CSO & Co-Founder

Paul Leonard is co-founder and CSO of RemedyBio, and is focused on the scientific leadership of the company. Paul is the lead inventor of Remedy technology and related patents and is supported by a diverse technical team within the company. Paul is also an Ass. Prof. of Biomedical Sciences at Dublin City University and prior to RemedyBio has held senior management roles at the cancer biotech companies Vaccinogen Inc. and WntResearch AB.

Paul holds a B.Sc. in Biotechnology and a Ph.D in Applied Immunology from Dublin City University and is a certified Lean Six Sigma Green Belt.

Colm Galligan

CMO

Colm Galligan is Chief Medical Officer of RemedyBIo, and is focussed on translating our technology’s potential into patient-centred outcomes. His experience as medical doctor, a pharmaceutical industry Medical Director and a patient advocate ideally places him to form innovative collaborations across scientific, clinical, patients & industry leaders.

Colm holds medical and MSc degrees from Trinity, as well as an MBA from UCD’s Smurfit Business School. He is a Fellow of the Faculty of Pharmaceutical Medicine (RCP UK). Colm is an active member of PKU Ireland and a former IPPOSI board member.

SUPPORTED BY

Recent News & Insights

News

RemedyBio wins major European funding for pioneering COVID-19 response technology

Irish Biotechnology company RemedyBio has received a multi-million euro  funding award from the European Innovation…
News

IRC Support

RemedyBio is now supported through funding from the Irish Research Council to investigate patient stratification…
News

Seriological Testing

RemedyBio's CSO Dr. Paul Leonard is leading an independent validation study of commercially available COVID-19…

Make an Enquiry

Mailing List

Get infrequent updates from the Remedy Biologics team about upcoming projects and announcements.